In the current study, we found that HSN748 treatment of RAS mutant–bearing AML mice increased the survival of these mice, possibly by inhibiting the RAS/MAPK pathway and downregulating PTPN11, IDH2, and WT1 genes, indicating the potential of HSN748 compound to eliminate the development of resistant subclones (Figure 3 and Supplemental Figure 7). This evidence concerns the gene IDH2 and acute myeloid leukemia.